Jean-Pierre RabÃ¨s

List of Publications by Year
in descending order

18 papers	3,161 citations	759233 12 h-index	888059 17 g-index
18 all docs	18 docs citations	18 times ranked	4115 citing authors

#	Article	IF	Citations
1	Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics, 2003, 34, 154-156.	21.4	2,532
2	Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with theAPOEp.Leu167del Mutation. Human Mutation, 2013, 34, 83-87.	2.5	103
3	Molecular Spectrum of Autosomal Dominant Hypercholesterolemia in France. Human Mutation, 2010, 31, E1811-E1824.	2.5	99
4	Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circulation: Cardiovascular Genetics, 2015, 8, 823-831.	5.1	90
5	Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. Current Atherosclerosis Reports, 2014, 16, 439.	4.8	87
6	APOE gene variants in primary dyslipidemia. Atherosclerosis, 2021, 328, 11-22.	0.8	60
7	Exome Sequencing in Suspected Monogenic Dyslipidemias. Circulation: Cardiovascular Genetics, 2015, 8, 343-350.	5.1	45
8	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. Atherosclerosis, 2018, 277, 334-340.	0.8	33
9	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. Scientific Reports, 2018, 8, 1943.	3.3	25
10	Familial hypercholesterolemia. Current Opinion in Lipidology, 2018, 29, 65-71.	2.7	24
11	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 1377-1392.	5.0	23
12	Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?. European Journal of Human Genetics, 2018, 26, 570-578.	2.8	22
13	Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families. Metabolites, 2021, 11, 564.	2.9	5
14	Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome. Archives of Cardiovascular Diseases, 2022, 115, 87-95.	1.6	5
15	APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia. International Journal of Molecular Sciences, 2022, 23, 5792.	4.1	4
16	Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. Medical Science Monitor, 2021, 27, e928784.	1.1	3
17	Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia. Metabolites, 2022, 12, 262.	2.9	1
18	A Simple RFLP-Based Method for HFE Gene Multiplex Amplification and Determination of Hereditary Hemochromatosis-Causing Mutation C282Y and H63D Variant with Highly Sensitive Determination of Contamination. BioMed Research International, 2020, 2020, 1-6.	1.9	0